Adalimumab: a new modality for Behçet's disease?
Authors:
- J A M van LaarJLJ A M van Laar
- T MissottenTMT Missotten
- P L A van DaelePDP L A van Daele
- A JamnitskiAJA Jamnitski
- G S BaarsmaGBG S Baarsma
- P M van HagenPHP M van Hagen
- 1 April 2007
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (4) , 565-566
Abstract
These patients were treated in the past with infliximab.9 Indications for anti-TNFα treatment were uveitis (patients 2 and 4), CNS disease (patients 3 and 5), colitis (patient 6) and severe oral ulcers and arthritis (patient 1), and are further presented in table 1. Symptoms were scored retrospectively since no official scoring system such as the Behcet’s Disease Current Activity Form (BDCAF) was available at the start of anti-TNFα treatment in our centre.Keywords
This publication has 9 references indexed in Scilit:
- [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].2006
- Current Concepts in the Etiology and Treatment of Behçet DiseaseSurvey of Ophthalmology, 2005
- The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus PanelSeminars in Arthritis and Rheumatism, 2005
- Anti-TNF- therapy for sight threatening uveitisBritish Journal of Ophthalmology, 2005
- Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a reviewAutoimmunity Reviews, 2005
- Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.2005
- Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritisSeminars in Arthritis and Rheumatism, 2003
- Vγ9Vδ2 T cells recovered from eyes of patients with Behçet's disease recognize non-peptide prenyl pyrophosphate antigensJournal of Neuroimmunology, 2002
- Behçet's DiseaseNew England Journal of Medicine, 1999